Point Mutation Cell Lines | Ubigene

Seoul, South Korea, 2022-Jan-05 — /EPR Network/ —

CRISPR-U™ Cell Line

CRISPR-U™ (based on CRISPR/Cas9 technology), developed by Ubigene, is more efficient than general CRISPR/Cas9 in double-strand breaking, and CRISPR-U™ can greatly improve the efficiency of homologous recombination, easily achieve knockout (KO)point mutation (PM) and knockin (KI) in vitro and in vivo. With CRISPR-U, Ubigene has successfully edit genes on more than 100 cell lines.

CRISPR/Cas9 recognizes the target sequence with gRNA, and guide Cas9 endonuclease to cut the upstream of PAM, resulting in the double-strand break (DSB) of the target site DNA. To repair the DSB, the cell uses its own DNA repair mechanism to add or delete or replace pieces of DNA sequences via Homology Directed Repair (HDR) or Non-Homologous End Joining (NHEJ).

Technical advantage
 Exclusive innovation, 10 times more efficient in gene-editing.
 Successfully edit genes on more than 100 types of cell lines.
Easily generate knockout (KO), point mutation (PM) and knockin (KI) in vitro and in vivo.
CRISPR-U™ offers a 100% mutation guarantee. No mutation, no charge!
Point Mutation Cell Lines
CRISPR/Cas9 and ssODN used to repair the point mutation in A79V-hiPSC. A) Genomic sequence surrounding the mutation site: mutated nucleotide (T, red); sgRNA recognition site containing 20 bp (yellow); CRISPR cutting site between the 17th and 18th bp (bold); forward and reverse primers (pink). B) ssODN with 120 bp, 60 bp upstream and 60 bp downstream the mutation site containing the WT nucleotide (C, green).
Point mutation Strategy
Point Mutation Cell Line
Work Flow and Validation
Work Flow and Validation
Case Study
The A79V mutation of PSEN1 gene can cause Alzheimer’s disease. Somatic cells of patients with Alzheimer’s disease are induced into pluripotent stem cells (iPSCs), and then the mutant gene is modified by replacing the point mutation with a wild-type sequence. By studying the iPSC of patients and the modified iPSC, we can know the effect of the mutation on cell phenotype, so as to further study the pathological effect of the mutation.
CRISPR/Cas9 and ssODN used to repair the point mutation in A79V-hiPSC.
CRISPR/Cas9 and ssODN used to repair the point mutation in A79V-hiPSC.
A) Genomic sequence surrounding the mutation site: mutated nucleotide (T, red); sgRNA recognition site containing 20 bp (yellow); CRISPR cutting site between the 17th and 18th bp (bold); forward and reverse primers (pink).
B) ssODN with 120 bp, 60 bp upstream and 60 bp downstream the mutation site containing the WT nucleotide (C, green).
Work Flow and Validation
B. Sequencing of exon 4 of the PSEN1 gene in hiPSCs.
A) Heterozygous c.236C>T substitution in the mother line previously published.
B) Successful correction of the point mutation (T>C).
Reference:
Fukuda, N., Senga, Y., & Honda, S. (2019). Anxa2‐and Ctsd‐knockout CHO cell lines to diminish the risk of contamination with host cell proteins. Biotechnology progress, e2820.

contact

TEL : +86 153 6067 3248 (Int’l)

US Toll free:855 777 3210

EU Toll free:800 3272 9252

Korea Toll free:001 800 3272 9252 (Telecom)

E-mail:sophia@ubigene.com

www.ubigene.us

Matched content

Editor’s pick

Express Press Release Distribution